Everest Medicines Ltd
HKEX:1952
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.54
39.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Everest Medicines Ltd
Cash from Investing Activities
Everest Medicines Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Everest Medicines Ltd
HKEX:1952
|
Cash from Investing Activities
¥752.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Investing Activities
¥117.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Investing Activities
-¥2.1B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Investing Activities
-¥1.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-30%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Investing Activities
-¥837.9m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-12%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Investing Activities
-¥1.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-102%
|
CAGR 10-Years
N/A
|
|
Everest Medicines Ltd
Glance View
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
See Also
What is Everest Medicines Ltd's Cash from Investing Activities?
Cash from Investing Activities
752.5m
CNY
Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Cash from Investing Activities amounts to 752.5m CNY.
You don't have any saved screeners yet
